Logo

esophageal cancer

Esophageal Cancer Molecular Study Highlights Tumor Subtypes, Treatment Response Markers

Researchers found four esophageal squamous cell carcinoma molecular subtypes by generating genomic, transcriptomic, epigenetic, and proteomic profiles for more than 150 cases.

ProPhase Labs to Acquire Stella Diagnostics Esophageal Cancer Screening Test for $4.5M

The agreement gives ProPhase exclusive global rights to Stella's BE-Smart Esophageal Pre-Cancer screening test and related intellectual property assets.

Castle Bio Q2 Growth Driven by Skin Cancer Testing as New Acquisitions Boost Sales
Premium

The company reported a record number of tests in the quarter led by its skin cancer menu but with notable sales in other test categories. 

Immuno-Genomic Features Predict Treatment Response in Esophageal Carcinoma

Researchers developed a machine learning tool that combines the features to predict response to platinum-based neoadjuvant chemotherapy.

QIMR Berghofer Licenses Esophageal Cancer Blood Biomarkers to Proteomics International

Under the agreement, Proteomics International has the right to use the markers to develop and commercialize a blood-based early detection test for esophageal cancer.

May 9, 2022

Castle Biosciences Q1 Revenues Grow 18 Percent

Mar 31, 2022

New Esophageal Cancer Tests on Horizon as Hopkins Spinout Capsulomics Preps Clinical Launch
Premium

Mar 29, 2022

Lucid Diagnostics Reports $300K in Preliminary Q4 Revenues

Mar 3, 2022

Lucid Diagnostics Acquires Laboratory Assets From ResearchDx for $6.2M

Mar 2, 2022

Castle Bio Adds Data for DecisionDx Melanoma Assay, Eyes Squamous Cell Carcinoma Reimbursement
Premium

Feb 28, 2022

Castle Biosciences Q4 Revenues Grow 45 Percent

Nov 17, 2021

Newly Public Lucid Diagnostics Posts $200K in Preliminary Q3 Revenues

Nov 8, 2021

BTIG, Canaccord Genuity Initiate Coverage of Lucid Diagnostics With Buy Ratings

Oct 27, 2021

Castle Biosciences Buy of Cernostics Aligns With Goal to Diversify Portfolio
Premium

Oct 19, 2021

Castle Biosciences Acquires Cernostics for up to $80M

Oct 14, 2021

Lucid Diagnostics Prices $70M IPO, Starts Trading on Nasdaq

Jul 13, 2021

Gastric Cancer Cases Frequently Harbor Genetic Risk Variants, Suggesting Germline Testing

Jun 10, 2021

Lucid Diagnostics Obtains CE Mark for Esophageal Cancer Molecular Test

Feb 18, 2021

Stella Diagnostics, Mayo Clinic Collaborating on Barrett's Esophagus Protein Markers

Oct 12, 2020

Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test

Sep 24, 2020

Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

Sep 8, 2020

Early Copy Number Changes Predict Progression of Barrett's Esophagus to Esophageal Cancer

Aug 6, 2020

PavMed Raises $7M in Private Funding Round

Jul 1, 2020

AnchorDx Demonstrates Liquid Biopsy DNA Methylation Test for Early Cancer Detection
Premium

May 11, 2020

Genetic Ancestry Linked to Differences in Molecular Features of Cancers

Breaking News
The Scan

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.

DNA Biobank Developed for French Kidney Donors, Recipients

The KiT-GENIE biobank described in the European Journal of Human Genetics contains DNA samples, genotyping profiles, immune patterns, and clinical features for thousands of kidney donors or transplant recipients in Nantes, France.

Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut

By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site.

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.